Literature DB >> 30778524

Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.

Kim L Ho1, Liyan Zhang1, Cory Wagg1, Rami Al Batran1,2, Keshav Gopal1,2, Jody Levasseur1, Teresa Leone3, Jason R B Dyck1, John R Ussher1,2, Deborah M Muoio4, Daniel P Kelly3, Gary D Lopaschuk1.   

Abstract

AIMS: The failing heart is energy-starved and inefficient due to perturbations in energy metabolism. Although ketone oxidation has been shown recently to increase in the failing heart, it remains unknown whether this improves cardiac energy production or efficiency. We therefore assessed cardiac metabolism in failing hearts and determined whether increasing ketone oxidation improves cardiac energy production and efficiency. METHODS AND
RESULTS: C57BL/6J mice underwent sham or transverse aortic constriction (TAC) surgery to induce pressure overload hypertrophy over 4-weeks. Isolated working hearts from these mice were perfused with radiolabelled β-hydroxybutyrate (βOHB), glucose, or palmitate to assess cardiac metabolism. Ejection fraction decreased by 45% in TAC mice. Failing hearts had decreased glucose oxidation while palmitate oxidation remained unchanged, resulting in a 35% decrease in energy production. Increasing βOHB levels from 0.2 to 0.6 mM increased ketone oxidation rates from 251 ± 24 to 834 ± 116 nmol·g dry wt-1 · min-1 in TAC hearts, rates which were significantly increased compared to sham hearts and occurred without decreasing glycolysis, glucose, or palmitate oxidation rates. Therefore, the contribution of ketones to energy production in TAC hearts increased to 18% and total energy production increased by 23%. Interestingly, glucose oxidation, in parallel with total ATP production, was also significantly upregulated in hearts upon increasing βOHB levels. However, while overall energy production increased, cardiac efficiency was not improved.
CONCLUSIONS: Increasing ketone oxidation rates in failing hearts increases overall energy production without compromising glucose or fatty acid metabolism, albeit without increasing cardiac efficiency. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Beta-hydroxybutyrate; Cardiac Energy metabolism; Heart failure; Hypertrophy; Ketone body oxidation

Mesh:

Substances:

Year:  2019        PMID: 30778524      PMCID: PMC6704391          DOI: 10.1093/cvr/cvz045

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  64 in total

1.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

Authors:  P J RANDLE; P B GARLAND; C N HALES; E A NEWSHOLME
Journal:  Lancet       Date:  1963-04-13       Impact factor: 79.321

2.  Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism.

Authors:  R J BING; A SIEGEL; I UNGAR; M GILBERT
Journal:  Am J Med       Date:  1954-04       Impact factor: 4.965

3.  Myocardial metabolism in congestive heart failure.

Authors:  R E OLSON; W B SCHWARTZ
Journal:  Medicine (Baltimore)       Date:  1951-02       Impact factor: 1.889

4.  An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure.

Authors:  M Taylor; T R Wallhaus; T R Degrado; D C Russell; P Stanko; R J Nickles; C K Stone
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

5.  Glucose and fatty acid metabolism in the isolated working mouse heart.

Authors:  D D Belke; T S Larsen; G D Lopaschuk; D L Severson
Journal:  Am J Physiol       Date:  1999-10

6.  Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure.

Authors:  Juan Carlos Osorio; William C Stanley; Axel Linke; Michele Castellari; Quy N Diep; Ashish R Panchal; Thomas H Hintze; Gary D Lopaschuk; Fabio A Recchia
Journal:  Circulation       Date:  2002-07-30       Impact factor: 29.690

7.  Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.

Authors:  Víctor G Dávila-Román; Giridhar Vedala; Pilar Herrero; Lisa de las Fuentes; Joseph G Rogers; Daniel P Kelly; Robert J Gropler
Journal:  J Am Coll Cardiol       Date:  2002-07-17       Impact factor: 24.094

8.  Comprehensive transthoracic cardiac imaging in mice using ultrasound biomicroscopy with anatomical confirmation by magnetic resonance imaging.

Authors:  Yu-Qing Zhou; F Stuart Foster; Brian J Nieman; Lorinda Davidson; X Josette Chen; R Mark Henkelman
Journal:  Physiol Genomics       Date:  2004-07-08       Impact factor: 3.107

9.  The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy.

Authors:  Lazaros A Nikolaidis; Anthony Sturzu; Carol Stolarski; Dariush Elahi; You-Tang Shen; Richard P Shannon
Journal:  Cardiovasc Res       Date:  2004-02-01       Impact factor: 10.787

10.  beta-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content.

Authors:  William C Stanley; Steven R Meadows; Krista M Kivilo; Bridgette A Roth; Gary D Lopaschuk
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-10       Impact factor: 4.733

View more
  47 in total

1.  Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure.

Authors:  Senthil Selvaraj; Daniel P Kelly; Kenneth B Margulies
Journal:  Circulation       Date:  2020-06-01       Impact factor: 29.690

2.  Exogenous ketones in the healthy heart: the plot thickens.

Authors:  Senthil Selvaraj; Kenneth B Margulies
Journal:  Cardiovasc Res       Date:  2021-03-21       Impact factor: 10.787

3.  Remodeling of substrate consumption in the murine sTAC model of heart failure.

Authors:  Aslan Turer; Francisco Altamirano; Gabriele G Schiattarella; Herman May; Thomas G Gillette; Craig R Malloy; Matthew E Merritt
Journal:  J Mol Cell Cardiol       Date:  2019-07-21       Impact factor: 5.000

4.  Increasing mitochondrial ATP synthesis with butyrate normalizes ADP and contractile function in metabolic heart disease.

Authors:  Marcello Panagia; Huamei He; Tomas Baka; David R Pimentel; Dominique Croteau; Markus M Bachschmid; James A Balschi; Wilson S Colucci; Ivan Luptak
Journal:  NMR Biomed       Date:  2020-02-17       Impact factor: 4.044

Review 5.  Disruption of energy utilization in diabetic cardiomyopathy; a mini review.

Authors:  Shinsuke Nirengi; Carmem Peres Valgas da Silva; Kristin I Stanford
Journal:  Curr Opin Pharmacol       Date:  2020-09-25       Impact factor: 5.547

Review 6.  Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.

Authors:  Rachel J Perry; Gerald I Shulman
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

7.  Ketone body can be a fuel substrate for failing heart.

Authors:  Michinari Nakamura; Junichi Sadoshima
Journal:  Cardiovasc Res       Date:  2019-09-01       Impact factor: 10.787

Review 8.  Cardiac Energy Metabolism in Heart Failure.

Authors:  Gary D Lopaschuk; Qutuba G Karwi; Rong Tian; Adam R Wende; E Dale Abel
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 9.  Ketone body metabolism in diabetic and non-diabetic heart failure.

Authors:  Ningjing Qian; Yaping Wang
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

Review 10.  Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Konstantinos E Iliodromitis; Sotiria G Giotaki; Charalampos Kossyvakis; Konstantinos Raisakis; Andreas Kaoukis; Vaia Lambadiari; Dimitrios Avramides; Bernhard Reimers; Giulio G Stefanini; Michael Cleman; Georgios Giannopoulos; Alexandra Lansky; Spyridon G Deftereos
Journal:  Drugs       Date:  2021-07-23       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.